EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Avrobio's Enterprise Value is $-41.93 Mil.
Avrobio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $12.03 Mil. Therefore, Avrobio's EV-to-EBIT for today is -3.48.
The historical rank and industry rank for Avrobio's EV-to-EBIT or its related term are showing as below:
AVRO'
s EV-to-EBIT Range Over the Past 10 Years
Min: -3.71 Med: 0 Max: 17.04
Current: -3.48
During the past 8 years, the highest EV-to-EBIT of Avrobio was 17.04. The lowest was -3.71. And the median was 0.00.
AVRO's EV-to-EBIT is ranked better than 99.08% of 433
companies
in the Biotechnology industry
Industry Median: 9.43
vs AVRO: -3.48
The historical data trend for Avrobio's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Avrobio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avrobio's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avrobio's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Avrobio's EV-to-EBIT falls into.
Avrobio's current Enterprise Value is $-41.93 Mil.
Avrobio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avrobio (NAS:AVRO) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Avrobio's Enterprise Value for the quarter that ended in Dec. 2023 was $-36.41 Mil.
Avrobio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avrobio EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Avrobio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; AVR-RD-06 for the treatment of Gaucher disease type 3; and AVR-RD-03 for the treatment of Pompe disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AVRO has been successfully added to your 